# Pathway Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pathway-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.pathwaytx.com
- Total disclosed funding: $24M
- Latest round: Series A (May 25, 2011)
- Investors on record: 5

## About

Pathway Therapeutics Inc. is a healthcare technology firm specializing in innovative solutions that enhance healthcare delivery efficiency, focusing on digital health platforms that improve patient engagement and clinical data management.Pathway Therapeutics Inc. is engaged in the development of advanced healthcare technology solutions. Founded in 2008 and headquartered in San Francisco, US, the company has undergone significant developments in its business strategy. The firm has secured a total of USD 7.50 mn through multiple funding rounds, with the most recent being a VENTURE DEBT round in August 2013, raising USD 0.40 mn. The company has been involved in 7 deals overall, with a notable acquisition of its targeted anti-cancer drug by VetDC.PathwayTX specializes in developing innovative technology solutions designed to enhance the efficiency and effectiveness of healthcare delivery. The company's core product offerings include a comprehensive digital health platform that integrates clinical data management, patient engagement tools, and analytics capabilities. These solutions aim to streamline workflows for healthcare providers while improving patient outcomes through more personalized care. PathwayTX caters primarily to healthcare institutions, including hospitals, clinics, and private practices, facilitating better coordination of care among providers and patients. Their products are utilized in various geographical markets, including the United States, Canada, and select European countries, where the demand for advanced digital health solutions continues to grow.PathwayTX generates revenue through a B2B transaction structure, primarily involving subscription-based models for their digital health platform. Clients typically engage in annual agreements that provide them access to the full suite of features, including data analytics and patient management tools. The pricing plans are tiered based on the size of the healthcare institution and the specific features utilized, ensuring that organizations can select an option that best fits their needs. Flagship products within their offerings feature capabilities that allow for customizable interfaces and integration with existing healthcare systems, enhancing the overall user experience. This structured approach to revenue generation allows PathwayTX to establish long-term partnerships with clients, ensuring sustained growth and stability within their business model.Pathway Therapeutics Inc. plans to leverage recent funding to enhance its product offerings and expand into new markets. The company is developing new features for its digital health platform, aiming for a release by the end of 2024. Additionally, it targets expansion into additional European markets and the Asia-Pacific region by 2025. The funding raised in August 2013 will support these initiatives, focusing on enhancing technology capabilities and broadening market reach.

## Funding rounds

- Series A, May 25, 2011, $7.5M — GBS Venture Partners, CM Capital Investments
- Series A, Aug 10, 2010, $4.5M — GBS Venture Partners, New Zealand Growth Capital Partners, CM Capital Investments, Trans-Tasman Commercialization Fund
- Series A, Oct 9, 2009, $2.4M — GBS Venture Partners, CM Capital Investments, Auckland Uniservices Limited, Trans-Tasman Commercialization Fund
- Series A, Jun 18, 2008, $9.6M — GBS Venture Partners, CM Capital Investments

## Investors

- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series A
- CM Capital Investments — Series A
- Auckland Uniservices Limited — Series A
- Trans-Tasman Commercialization Fund — Series A
- New Zealand Growth Capital Partners — Series A